Cure8

Why This Matters

Zinc deficiency was associated with changes in intestinal barrier proteins and higher IL‑17 in Crohn’s disease biopsies, which could be relevant to inflammation and mucosal healing.

Who Should Pay Attention

Adults with Crohn’s disease, clinicians managing nutritional status and inflammation in IBD, and researchers studying mucosal immunity or nutritional interventions.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

This retrospective observational study compared paired colonoscopic biopsies from the same Crohn’s patients when their serum zinc was low versus when it was normal. Immunohistochemistry was used to measure tight junction proteins and proinflammatory cytokines.

The main analysis included 12 patients; a subanalysis included 8 patients who did not receive treatment intensification. The study found an association (not proof of causation) between low serum zinc and changes in mucosal barrier protein expression and increased IL‑17.

The authors suggest these findings could mean zinc status influences epithelial barrier integrity and mucosal immune responses in Crohn’s disease and note that zinc supplementation might be a simple adjunct to explore further.

Keep In Mind

Findings come from a small retrospective study (paired biopsies, n=12 main analysis). Associations do not prove causality; further larger and prospective studies are needed before routine changes to care.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationJGH open : an open access journal of gastroenterology and hepatology
AuthorsAsako Nomura, Shinsuke Otagiri, Takehiko Katsurada +3 more
InstitutionDepartment of Gastroenterology and Hepatology Hokkaido University Graduate School of Medicine Sapporo Hokkaido Japan.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 23, 2026, 12:00 AM
Content availableJournal abstract

Conflict statement: Naoya Sakamoto has received lecture fees from Gilead Sciences, AbbVie, Chugai Pharmaceutical Co. Ltd., and AstraZeneca PLC, as well as research grants from Chugai Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd., Shionogi & Co. Ltd., and Eisai Co. Ltd. Shinsuke Otagiri received a research grant from Mochida Pharmaceutical Co. Ltd. The other authors declare no conflicts of interest.

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →